DDInter1214 DDInter1676
Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hematopoietic tumors. It was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Midostaurin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Midostaurin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Midostaurin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Saxagliptin
Midostaurin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Midostaurin {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Midostaurin {u} may lead to a major life threatening interaction when taken with {v} Crizotinib
Midostaurin may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Midostaurin may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Midostaurin may lead to a major life threatening interaction when taken with Leflunomide
Midostaurin may lead to a major life threatening interaction when taken with Crizotinib